Citadel Advisors
AGIO icon

Citadel Advisors’s Agios Pharmaceuticals AGIO Stock Holding History

Citadel Advisors’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$21M Sell
619,613
-729,355
-54% -$20.7M ﹤0.01% 2286
2025
Q4 		$36.7M Buy
1,348,968
+856,986
+174% +$30.1M 0.01% 1717
2025
Q3 		$19.7M Sell
491,982
-589,488
-55% -$22.2M ﹤0.01% 2358
2025
Q2 		$36M Buy
1,081,470
+217,971
+25% +$6.61M 0.01% 1514
2025
Q1 		$25.3M Sell
863,499
-570,177
-40% -$18.9M ﹤0.01% 1770
2024
Q4 		$47.1M Buy
1,433,676
+1,421,940
+12,116% +$66.8M 0.01% 1319
2024
Q3 		$521K Sell
11,736
-112,104
-91% -$5.09M ﹤0.01% 8174
2024
Q2 		$5.34M Sell
123,840
-878,621
-88% -$31.7M ﹤0.01% 3643
2024
Q1 		$29.3M Sell
1,002,461
-72,351
-7% -$1.94M 0.01% 1685
2023
Q4 		$23.9M Buy
1,074,812
+658,194
+158% +$14.7M ﹤0.01% 1836
2023
Q3 		$10.3M Buy
416,618
+241,427
+138% +$6.39M ﹤0.01% 2654
2023
Q2 		$4.96M Sell
175,191
-107,963
-38% -$2.69M ﹤0.01% 3669
2023
Q1 		$6.5M Buy
283,154
+64,137
+29% +$1.7M ﹤0.01% 3391
2022
Q4 		$6.15M Sell
219,017
-30,635
-12% -$863K ﹤0.01% 3525
2022
Q3 		$7.06M Sell
249,652
-83,929
-25% -$2.25M ﹤0.01% 3305
2022
Q2 		$7.39M Buy
333,581
+301,818
+950% +$6.82M ﹤0.01% 3111
2022
Q1 		$925K Buy
31,763
+11,534
+57% +$352K ﹤0.01% 7887
2021
Q4 		$665K Sell
20,229
-78,253
-79% -$3.15M ﹤0.01% 8959
2021
Q3 		$4.54M Buy
+98,482
New +$4.76M ﹤0.01% 4488
2021
Q2 		– Sell
-179,873
Closed -$10.1M – 13586
2021
Q1 		$9.29M Buy
179,873
+159,051
+764% +$7.88M ﹤0.01% 3082
2020
Q4 		$902K Sell
20,822
-181,609
-90% -$7.18M ﹤0.01% 7013
2020
Q3 		$7.08M Buy
202,431
+99,032
+96% +$4.34M ﹤0.01% 2685
2020
Q2 		$5.53M Sell
103,399
-381,542
-79% -$17.7M ﹤0.01% 2947
2020
Q1 		$17.2M Buy
484,941
+240,568
+98% +$11.1M 0.01% 1354
2019
Q4 		$11.7M Sell
244,373
-111,529
-31% -$4.22M 0.01% 2041
2019
Q3 		$11.5M Sell
355,902
-275,156
-44% -$11.4M 0.01% 2054
2019
Q2 		$31.5M Buy
631,058
+206,570
+49% +$11M 0.01% 1026
2019
Q1 		$28.6M Buy
424,488
+143,253
+51% +$8.34M 0.01% 1056
2018
Q4 		$13M Buy
281,235
+114,345
+69% +$7.06M 0.01% 1620
2018
Q3 		$12.9M Buy
166,890
+163,389
+4,667% +$13.1M 0.01% 1827
2018
Q2 		$295K Sell
3,501
-14,854
-81% -$1.3M ﹤0.01% 7234
2018
Q1 		$1.5M Sell
18,355
-73,115
-80% -$5.65M ﹤0.01% 4178
2017
Q4 		$5.23M Buy
+91,470
New +$5.76M ﹤0.01% 2428
2017
Q3 		– Sell
-155,353
Closed -$9.33M – 7471
2017
Q2 		$7.99M Buy
+155,353
New +$7.94M 0.01% 1637
2017
Q1 		– Sell
-21,066
Closed -$1.01M – 7380
2016
Q4 		$879K Sell
21,066
-261,653
-93% -$13.7M ﹤0.01% 4033
2016
Q3 		$14.9M Buy
+282,719
New +$12.3M 0.02% 1050
2016
Q1 		– Sell
-562
Closed -$24K – 6658
2015
Q4 		$36K Buy
+562
New +$36.9K ﹤0.01% 7539
2015
Q3 		– Sell
-38,374
Closed -$3.75M – 8834
2015
Q2 		$4.26M Buy
38,374
+25,603
+200% +$2.76M ﹤0.01% 2209
2015
Q1 		$1.2M Sell
12,771
-2,766
-18% -$310K ﹤0.01% 3697
2014
Q4 		$1.74M Sell
15,537
-126,915
-89% -$11.3M ﹤0.01% 3083
2014
Q3 		$8.74M Sell
142,452
-21,622
-13% -$932K 0.01% 1472
2014
Q2 		$7.52M Buy
+164,074
New +$6.69M 0.01% 1493

Other funds holding AGIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

Citadel Advisors's AGIO Position: Q1 2026 in Review

Citadel Advisors reduced its Agios Pharmaceuticals (AGIO) stake by 54% in Q1 2026, selling an estimated $20.7M and leaving 619,613 shares worth $21M. The position accounts for ﹤0.01% of the portfolio, ranked #2286.

Citadel Advisors first reported a position in AGIO in Q2 2014 and has held it in 42 quarters since. The position peaked at $47.1M in Q4 2024. 232 funds tracked by Wall St. Rank hold AGIO as of Q1 2026.

  • Citadel Advisors held 619,613 shares of Agios Pharmaceuticals worth $21M as of Q1 2026.
  • Citadel Advisors sold 729,355 Agios Pharmaceuticals shares in Q1 2026, an estimated $20.7M.
  • Agios Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #2286 holding.
  • Citadel Advisors first reported a position in Agios Pharmaceuticals in Q2 2014 and has held it in 42 quarters since.
  • Citadel Advisors's Agios Pharmaceuticals position peaked at $47.1M in Q4 2024.
  • 232 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.